Skip to the comparison

How to get a GLP-1 through the Medicare GLP-1 Bridge

Medicare GLP-1 Bridge from 1 Jul 2026 to 31 Dec 2027

Primary source

Not a news summary

Everything on this page is taken from the program's own documentation. Read it yourself before making a decision. Eligibility and formulary rules change, and this page is not insurance advice.

Medicare GLP-1 Bridge on cms.gov (opens in a new tab)

We track prices, terms and availability. We are not clinicians, this page is not medically reviewed, and nothing here is medical advice. Talk to a licensed clinician about whether a GLP-1 medication is right for you.

The order of events

This is the sequence in the CMS fact sheet (No. 12234, June 2026) and CMS's guidance for prescribers and pharmacies:

  1. You and your prescriber decide whether a covered drug fits, and whether you meet the eligibility rules.
  2. Your prescriber sends the prescription to a pharmacy.
  3. The pharmacy asks for your Medicare number. If you do not have your card, the pharmacist can look it up from the last four digits of your Social Security number.
  4. Once the pharmacy's claim confirms you are eligible, it asks your prescriber for a prior authorization.
  5. Your prescriber submits CMS's Medicare GLP-1 Bridge form, electronically or by fax.
  6. You and your prescriber are told the decision within 72 hours, and Medicare sends you a letter when the drug is covered.
  7. You pay $50 at the pharmacy for a one-month supply.

The prescriber and patient will be notified of the prior authorization decision within 72 hours.

CMS 17 Aug 2026 Primary source (opens in a new tab)

Refills and dose changes

The CMS fact sheet (No. 12234, June 2026) says a refill needs no new approval from Medicare as long as you stay on the same drug, even if your dose changes. Moving to a different drug is a different case, and CMS's material does not spell out how a switch is handled, so ask your prescriber before assuming the approval carries over.

Every fill is one month: CMS rules out 60- and 90-day fills.

If the answer is no

A prescriber may resubmit the prior authorization form if they initially entered incorrect information or have updated or additional information to include. There is no appeals process under Medicare GLP-1 Bridge.

CMS 6 Aug 2026 Primary source (opens in a new tab)

CMS lets your prescriber resubmit the form with corrected or added information. It provides no Bridge appeals process.

The pharmacy side

Pharmacies do not need to opt-in to participate in the Medicare GLP-1 Bridge. Claims are processed by Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, under BIN 028918 and PCN MEDDGLP1BR.

CMS 17 Aug 2026 Primary source (opens in a new tab)

If a pharmacy tells you it does not take the Bridge, the BIN and PCN above are what its claim goes to. CMS's guidance does not separate retail from mail order, so whether a mail-order pharmacy processes these claims is a question for that pharmacy.

The prescriber side

CMS says your prescriber does not need to be enrolled in Medicare to write the prescription or submit the form, but must not be on Medicare's Preclusion List. The form is signed under penalty of perjury and confirms the drug is prescribed with ongoing nutrition and activity changes. CMS's guidance does not mention telehealth. We have not established which telehealth companies submit the Bridge form, so ask before you book.

Questions readers ask

Can my telehealth prescriber submit the Bridge form?

CMS does not require Medicare enrollment to submit it, only that the prescriber is not on the Preclusion List. Whether a given telehealth company does it is up to that company.

Do I need a new approval when my dose goes up?

Not according to CMS's fact sheet, as long as you stay on the same drug.

More on the Medicare GLP-1 Bridge

How this site works

How we rate providers

Ratings weigh verified price, total first-year cost, state availability, speed to prescription, cancellation terms and regulatory record. Full scoring rubric.

No clinical review

We are not clinicians and this page carries no clinical review. Drug and regulatory facts are cited directly from FDA, CMS and court records, never a provider's marketing claims.

How we make money

When you sign up with a provider through our links, we may earn a referral fee. Fees never influence a rating, a price, or a position in a table. Full advertiser disclosure.